# US 2020/0270200 A1 · Deuterated compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0270200 A1
- Document ID: US20200270200A1
- Status: Published application
- Kind: A1
- Application number: 16/543,790
- Filed: 2019-08-19
- Published: 2020-08-27
- Earliest claimed: 2012-08-08
- Assignees: Biostatus Limited
- Applicants: Biostatus Limited
- Inventors: Stefan OGRODZINSKI; Paul SMITH; Stephanie MCKEOWN; Laurence PATTERSON; Rachel Jane ERRINGTON
- Web page: https://patentgrep.com/patent/US20200270200A1

## CPC

- C07C 225/36: the carbon skeleton being further substituted by singly-bound oxygen atoms
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/277: having a ring, e.g. verapamil
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 5/28: Antiandrogens
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/04: for throat disorders
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 59/001: {Acyclic or carbocyclic compounds}
- C07C 291/04: containing amino-oxide bonds
- G01N 31/225: {for oxygen, e.g. including dissolved oxygen}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07C 2603/24: Anthracenes; Hydrogenated anthracenes
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An anthraquinone compound of formula I (such as the compounds of formulae II to X) and processes for making the same are provided. Pharmaceutical compositions for use in the treatment of cancer, optionally in combination with an agent capable of reducing the level of oxygenation of a tumour, are also provided. Additionally, an option for combination with chemotherapeutic and radiotherapeutic modalities to enhance overall tumour cell kill is provided. Methods for the detection of cellular hypoxia, both in vivo and in vitro, are additionally provided.

## Claims

### Claim at position 1

-80. (canceled)

### Claim 81

A compound of Formula IV or VI:
wherein Y are each independently selected from the group consisting of hydrogen, hydroxy, halogeno, amino, C1-4 alkoxy and C2-8 alkanoxy.

### Claim 82 (depends on 81)

A compound according to claim 81, wherein the compound is of Formula VIII or X:

### Claim 83 (depends on 81)

A compound according to claim 81 wherein the compound is in the form of a halide salt, for example a chloride salt.

### Claim 84 (depends on 81)

A pharmaceutical composition comprising a compound according to claim 81 together with pharmaceutically acceptable buffer, diluent, carrier, adjuvant or excipient.

### Claim 85 (depends on 84)

A pharmaceutical composition according to claim 84 formulated for parenteral administration.

### Claim 86 (depends on 81)

A process for making a compound according to claim 81 comprising reacting an anthracene-9,10-dione with a deuterated alkylenediamine under conditions suitable for the production of an alkylaminoalkyl-aminoanthraquinone.

### Claim 87 (depends on 86)

A process according to claim 86 further comprising the step of reacting the alkylaminoalkylaminoanthraquinone with a monoperoxyphthalate to under conditions suitable for the production of an N-oxide derivative of the alkylamino-alkylaminoanthraquinone.

### Claim 88 (depends on 86)

A process according to claim 86 comprising reacting 1,4-difluoro-5,8-dihydroxyanthracene-9,10-dione, 281-005 with deuterated--N,N-dimethylethylene-diamine under conditions suitable for the production of 1,4-bis-{[2-(deuterated-d6-dimethylamino)ethyl]amino)-5,8-dihydroxyanthracene-9,10-dione.

### Claim 89 (depends on 88)

A process according to claim 88 further comprising the step of reacting the 1,4-bis-{[2-(deuterated-d6-dimethylamino)ethyl]amino)-5,8-dihydroxyanthracene-9,10-dione with magnesium monoperoxyphthalate under conditions suitable for the production of 1,4-bis-{[2-(deuterated-d6-dimethylamino-N-oxide)ethyl]amino)-5,8-dihydroxy-anthracene-9,10-dione.

### Claim 90 (depends on 81)

A method of treating cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 81.

### Claim 91 (depends on 90)

A method according to claim 90 wherein the patient is human.

### Claim 92 (depends on 90)

A method according to claim 90, wherein administering the therapeutically effective amount treats metastases or reduces metastatic spread.

### Claim 93 (depends on 90)

A method according to claim 90 wherein the compound is a monotherapy.

### Claim 94 (depends on 90)

A method according to claim 90 further comprising administering to the patient one or more additional cancer treatments.

### Claim 95 (depends on 94)

A method according to claim 94 wherein the one or more additional cancer treatments is/are selected from the group consisting of anti-androgens (steroidal and non-steroidal), vascular disrupting agents, anti-angiogenic agents, anti-VEGFR agents, IL8 inhibitors, NO synthase inhibitors, vasoconstricting agents, vasodilating agents, and radiotherapeutic modalities.

### Claim 96 (depends on 95)

A method according to claim 95 wherein the one or more additional cancer treatments is at least one anti-androgen.

### Claim 97 (depends on 96)

A method according to claim 96 wherein the at least one anti-androgen is selected from the group consisting of flutamide, nilutamide, bicalutamide, finasteride, dutasteride, bexlosteride, izonsteride, turosteride, epristeride and abiraterone.

### Claim 98 (depends on 97)

A method according to claim 97 wherein the at least one anti-androgen is bicalutamide.

### Claim 99

A method of detecting hypoxic cells in vitro or in vivo in a group of cells, the method comprising:
exposing a compound of Formula VI:
wherein Y are each independently selected from the group consisting of hydrogen, hydroxy, halogeno, amino, C1-4 alkoxy and C2-8 alkanoxy
to the group of cells;
analysing the cells for the presence of a corresponding reduced compound of Formula IV
and determining the hypoxic cells based on the presence of the corresponding reduced compound.

### Claim 100 (depends on 99)

The method according to claim 99 wherein the cells are mammalian, e.g. human.

### Claim 101 (depends on 99)

The method according to claim 99 in vitro.

### Claim 102 (depends on 99)

The method according to claim 99 in vivo.

### Claim 103 (depends on 102)

The method according to claim 102, further comprising:
surgically excising cells identified as being hypoxic.

### Claim 104 (depends on 99)

The method according to claim 99 wherein the compound is used in combination with a non-deuterated form of a compound of Formula VI.

### Claim 105 (depends on 99)

The method according to claim 99 wherein the compound is detected using a method selected from the group consisting of mass spectrometry, nuclear magnetic resonance, infrared spectroscopy, colorimetrically, Raman spectroscopy, nuclear magnetic resonance, affinity capture methods, immunohistochemistry, flow cytometry, microscopy and antibody-based detection methods.

### Claim 106 (depends on 81)

A kit of parts for use in detecting the oxygenation level of cells comprising a compound according to claim 81.

### Claim 107 (depends on 106)

A kit according to claim 106 further comprising a non-deuterated form of a compound of Formula VI.

### Claim 108 (depends on 94)

The method according to claim 94 wherein the one or more additional cancer treatments decreases tumour oxygenation in vivo.

### Claim 109 (depends on 108)

The method according to claim 108 wherein the one or more additional cancer treatments lowers the median oxygen level of the tumour to below 3%.

### Claim 110 (depends on 81)

The compound according to claim 81 wherein each Y is independently selected from the group consisting of hydrogen, hydroxy and halogeno.

### Claim 111 (depends on 81)

A method of treating a pancreatic cancer tumour in a patient comprising administering to the patient a therapeutically effective amount of the compound according to claim 81.

### Claim 112 (depends on 81)

A method of treating a prostate cancer tumour in a patient comprising administering to the patient a therapeutically effective amount of the compound according to claim 81.

### Claim 113 (depends on 112)

The method according to claim 112, wherein administering the therapeutically effective amount treats metastases or reduces metastatic spread.

### Claim 114 (depends on 112)

The method according to claim 112 further comprising administering to the patient one or more additional cancer treatments in combination with the therapeutically effective amount of the compound.

### Claim 115 (depends on 114)

The method according to claim 114 wherein the one or more additional cancer treatments is/are selected from the group consisting of anti-androgens (steroidal and non-steroidal), vascular disrupting agents, anti-angiogenic agents, anti-VEGFR agents, IL8 inhibitors, NO synthase inhibitors, vasoconstricting agents, vasodilating agents, and radiotherapeutic modalities.

### Claim 116 (depends on 115)

The method according to claim 115 wherein the one or more additional cancer treatments is at least one anti-androgen.

### Claim 117 (depends on 116)

The method according to claim 116 wherein the at least one anti-androgen is selected from the group consisting of flutamide, nilutamide, bicalutamide, finasteride, dutasteride, bexlosteride, izonsteride, turosteride, epristeride, abiraterone and combinations thereof.

### Claim 118 (depends on 117)

The method according to claim 117 wherein the at least one anti-androgen is bicalutamide.

### Claim 119 (depends on 114)

The method according to claim 114 wherein the one or more additional cancer treatments decreases tumour oxygenation in vivo.

### Claim 120 (depends on 119)

The method according to claim 119 wherein the one or more additional cancer treatments lowers the median oxygen level of the tumour to below 3%.
